Table 3. Iron Status Markers Evolution in Patients Who Completed the Study.
| ESA type: (n = 16)/CERA (n = 15) | Months of follow-up |
F | P | Partial η2 | ||
|---|---|---|---|---|---|---|
| 0 | 3 | 6 | ||||
| TSAT, % | ||||||
| EB | 26 ± 6 | 24 ± 7 | 30 ± 19 | 0.98 | 0.38 | |
| CERA | 35 ± 17 | 36 ± 14 | 29 ± 14 | 1.18 | 0.32 | |
| Ferritin, ng/mL | ||||||
| EB | 755 ± 397 | 707 ± 439 | 632 ± 343 | 0.78 | 0.45 | |
| CERA | 879 ± 542 | 783 ± 443 | 561 ± 301a | 7.17 | < 0.01b | 0.33 |
| Transferrin, mg/dL | ||||||
| EB | 161 ± 30 | 162 ± 22 | 158 ± 24 | 0.25 | 0.77 | |
| CERA | 183 ± 50 | 172 ± 37 | 164 ± 35a | 3.39 | 0.04 | 0.19 |
| Fe, µg/dL | ||||||
| EB | 59 ± 16 | 55 ± 15 | 67 ± 38 | 0.77 | 0.46 | |
| CERA | 83 ± 33 | 83 ± 35 | 64 ± 27 | 1.81 | 0.18 | |
| TIDC, mg | ||||||
| EB | 1,559 ± 310 | 1,565 ± 337 | 1,580 ± 299 | 0.05 | 0.95 | |
| CERA | 1,566 ± 344 | 1,609 ± 382 | 1,600 ± 364 | 0.19 | 0.82 | |
Values are given as mean (standard deviation (SD)). aP < 0.05 respect to baseline. bP < 0.05 after iron adjustment. CERA: continuous erythropoietin receptor activator; EB: epoetin-β; ESA: erythropoietin-stimulating agent; Fe: serum iron; TIDC: total iron deficit calculated; TSAT: transferrin saturation index.